Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation (eRFA)

This study has been completed.
Angiodynamics, Inc.
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
First received: December 11, 2007
Last updated: October 28, 2015
Last verified: October 2015
In this protocol we combine two available and reliable treatments - lumpectomy and RFA. This combination method will provide for excision of the cancer as routinely accomplished and ablation of the cancer bed (lumpectomy site) to ensure negative margins without removing large volumes of tissue. This combined open technique will allow for full histologic analysis of the primary tumor and margin. Because no extra tissue is removed from the breast to generate negative margins it will result in better cosmesis than re-excision to obtain negative margins.

Condition Intervention Phase
Cancer of the Breast
Device: AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation

Resource links provided by NLM:

Further study details as provided by University of Arkansas:

Primary Outcome Measures:
  • Number of Patients Requiring 2nd Surgery for Close or Positive Margins [ Time Frame: Margins assessed at Final Pathology, approximately 1 week post-RF surgery ] [ Designated as safety issue: No ]
    A "close" surgical margin implies that cancer cells are found on pathology to be very close to the surgical margin, and a "wide" surgical margin implies the tumor exists far from the cut edge or the surgical margin. For this study, we defined "close" as less than 3 mm.

Secondary Outcome Measures:
  • Recurrence of Breast Cancer at Prior Site of Disease [ Time Frame: Until study end (2 years) ] [ Designated as safety issue: No ]

Enrollment: 107
Study Start Date: September 2004
Study Completion Date: December 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
This is a non-randomized one arm study, all subjects receive treatment (radiofrequency ablation).
Device: AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)
Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.

Detailed Description:
While RFA alone is not approved for tumor destruction in breast it is FDA-approved for ablation of soft tissue after the breast cancer is removed. This study seeks to remove the tumor and then ablate a tumor-free zone (margin) of tissue around the lumpectomy site instead of removing more tissue. The primary short-term goal is to obviate the need for re-excision in the event of close or positive margins (< 3 mm) which occurs on average in ~40 percent of the cases. Permanent pathology is only an estimation of margin status since 90% of recurrences occur at the site of the original lumpectomy. RFA ensures a sterilized margin regardless of the accuracy of the permanent pathology.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female, 18-100 years old
  • Not pregnant or breastfeeding
  • Pre-study radiologic documentation of:
  • size ≤ 5 cm
  • unicentric, unilateral
  • suspicious mass or calcification
  • BIRADS classification ≥ IV
  • location of abnormality > 1 cm from skin
  • Ductal or Infiltrating Ductal Carcinoma
  • Grade I-III on final pathology
  • Good general health
  • Zubrod Performance Status of 0,1, or 2
  • No previous chemotherapy
  • No palpable axillary or supraclavicular lymph nodes
  • If prior non-breast malignancy, must have > 5 year disease-free survival

Exclusion Criteria:

  • Patient < 18 y/o or > 100 y/o
  • Pregnant or breastfeeding
  • Male
  • Breast implants
  • Multicentric disease or bilateral disease
  • Lesions > 5 cm in diameter
  • Lesions < 1.0 cm from the skin
  • Previous prior radiation to the breast
  • Need for mastectomy
  • Diffuse microcalcifications (as determined by the Investigator)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00571987

United States, Arkansas
University of Arkansas For Medical Sciences
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
University of Arkansas
Angiodynamics, Inc.
Principal Investigator: V. Suzanne Klimberg, M.D. University of Arkansas
  More Information

Additional Information:
Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT00571987     History of Changes
Other Study ID Numbers: UAMS 29143
Study First Received: December 11, 2007
Results First Received: July 29, 2015
Last Updated: October 28, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by University of Arkansas:
Breast cancer
Radiofrequency Ablation
Negative margins
Breast Conserving Surgery

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases

ClinicalTrials.gov processed this record on November 30, 2015